Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes but results in a disproportionately high morbidity and mortality. While chronic hypertension accounts for the majority of ICH, other common causes include cerebral amyloid angiopathy, sympathomimetic drugs of abuse, and underlying cerebral vascular anomalies. Validated baseline predictors of clinical outcome after ICH include the initial Glasgow Coma Scale score, hematoma volume, presence and amount of intraventricular hemorrhage, infratentorial ICH location, and advanced age. Although no treatment of proven benefi t currently exists for ICH, several recent large clinical trials have demonstrated the feasibility of investigation of surgical and medical treatments for ICH. Clinical research into ICH mechanisms of injury has demonstrated that hematoma expansion is common, even in patients without coagulopathy. Basic research has suggested that perihematomal injury is more likely related to toxicity of blood and iron in the brain ("neurohemoinfl ammation") rather than primary ischemic injury. Current guidelines for ICH treatment emphasize blood pressure management, urgent and rapid correction of coagulopathy, and surgery for
Intracerebral hemorrhage (ICH) is a common neurologic emergency. It is defi ned as bleeding into the brain parenchyma that is distinct from subarachnoid hemorrhage (SAH) and isolated intraventricular hemorrhage (IVH). It is expected that the incidence of ICH will increase as the overall population ages [ 1 ] ; thus, intimate knowledge of this entity is important for a wide variety of medical practitioners from the emergency room to the intensive care unit (ICU). Neurologists play an essential role in the care of these patients and are often the only practitioner with a longitudinal understanding of the spectrum of ICH care, including the emergency room, ICU, and longterm outcome. In addition to participating in dayto-day medical management, neurologists are often relied upon to make critical decisions regarding the utility of emergency interventions, determination of prognosis, and more recently in the design and implementation of basic research and clinical trials of novel therapeutics for the acute treatment of ICH.
Epidemiology
ICH accounts for 10-15% of the approximately 700,000 annual strokes in the USA [ 1 ] . The incidence of ICH in the USA is approximately 12-15 cases per 100,000 [ 2 ] . Primary ICH is due to rupture of small arterioles. In most cases it is due to the effects of long-standing hypertension on these small vessels, accounting for approximately 60-70% of all ICH [ 3 ] . Cerebral amyloid angiopathy (CAA) is an increasingly recognized cause of primary ICH, particularly in elderly patients. Recurrent hemorrhage risk from amyloid deposition is tripled with the presence of the e (epsilon)2 and e (epsilon)4 alleles of the apolipoprotein E gene [ 4 ] . Seco ndary ICH occurs in the context of an underlying pathology that predisposes the patient to hemorrhage (e.g., vascular malformation or tumor). Other important etiologies of both primary and secondary ICH include coagulopathy, sympathomimetic drugs of abuse, vasculitides, and moyamoya (Table 9 .1 ). The etiology of ICH is usually ascribed from consideration of the combination of the clinical presentation, patient risk factors, and imaging characteristics of the hemorrhage. Typical locations for hypertensive ICH include the basal ganglia, thalamus, cerebellum, pontine tegmentum, and deep lobar white matter ( Fig. 9.1 ). Hemorrhages due to CAA are usually located in the peripheral lobar white matter near the gray and white matter interface.
Recent meta-analysis and study of pooled prospective data continue to refi ne our understanding of the risk factors for ICH. Hypertension, age, ethnicity, high alcohol intake, and lower LDL-C have all been variably reported to contribute to [5] [6] [7] . Excessive alcohol use also increases the risk of ICH independent of its propensity to cause hypertension (OR 2.12 with >36 g/day of alcohol and OR 4.86 with >100 g/day) [ 8, 9 ] . Multiple retrospective and prospective cohort studies have demonstrated that high levels of LDL-C and triglycerides appear to have a protective effect in regard to ICH risk [ 6, 10, 11 ] . In a recent retrospective study, lower LDL-C levels (<100 mg/dl versus >100 mg/dl) were correlated with increased risk for mortality in patients presenting with ICH [ 12 ] . The SPARCL trial also demonstrated that high-dose atorvastatin in patients with recent stroke may increase the risk of ICH [ 13, 14 ] . Conversely, statin use prior to index presentation with ICH is associated with lower initial hematoma volumes but no independent effect on mortality or functional outcome in one prospective observational study [ 15 ] , while in another study (that did not report nor control for ICH volume), premorbid statin use was associated with better functional outcomes [ 16 ] . Nonwhite race has also been consistently associated with higher rates of ICH. While this is likely due in large part to access to care and subsequent poorly controlled hypertension, disparities in ICH rates between blacks and whites (relative risk 1.89 for blacks) cannot be completely explained by socioeconomic factors alone [ 6, 17 ] . Hispanic and Asian patients also have higher rates of ICH, which may be partially explained by higher rates of cerebral vascular anomalies such as cavernous malformations and moyamoya disease [ 18, 19 ] . Nonmodifi able risk factors for ICH include age, which imparts a relative risk increase of 1.97 per decade [ 5, 6 ] , and male gender, which has been variably identifi ed as a risk factor for ICH. Males may be predisposed to deep ICH more than lobar hemorrhages due to their higher rates of hypertension [ 20 ] . Although ICH comprises a minority of strokes that occur in the USA, it accounts for a disproportionately large amount of the total morbidity, mortality, and economic burden of stroke. Less than one-third of patients will be functionally independent after experiencing an ICH [ 21 ] . The shortterm mortality of ICH in most series is approximately 40% and has not improved significantly in recent years despite the growth of neurointensive care. While this is a direct refl ection of the absence of any effective proven treatments for ICH, there is also concern that heterogeneity in care and early care limitations may lead to selffulfi lling prophecies of poor outcome [22] [23] [24] [25] . Amongst survivors of ICH, health-related quality of life at 90 days is also signifi cantly diminished compared with the general population, and many baseline demographic factors (age, severity of initial neurologic defi cit, systolic blood pressure (SBP), ICH volume, deep as opposed to lobar ICH, and early worsening of neurologic status) appear to mediate this relationship [ 26 ] . Depression is also prevalent in ICH survivors and may account for this decrement in quality of life in ICH survivors [ 27 ] . The economic burden of ICH is tremendous, approaching six billion dollars annually in the USA, and approximately $165,000 per patient/year [28] [29] [30] .
Pathophysiology
The underlying pathologic process that predisposes to the rupture of small arterioles (<100 m m diameter) in hypertensive ICH has been termed lipohyalinosis. This process is characterized by subintimal fi broblast proliferation, deposition of lipid-fi lled macrophages, and replacement of smooth muscle cells in the tunica media of the larger vessels with collagen (see Fig. 9 .1 ) [ 31 ] . This leads to reduced blood vessel elasticity and increased susceptibility to spontaneous rupture.
The loss of neurologic function due to ICH has classically been ascribed to the tissue destruction caused by the initial hemorrhage as blood transects white matter tracts and destroys neurons. More recently, the importance of damage caused by mechanical effects of the hematoma has been replaced by interest in mechanisms of secondary brain injury. This has been spurred by the observation that many patients deteriorate clinically, without rehemorrhage, in the same time frame in which edema is developing and clot absorption and breakdown are occurring. There is increasing evidence that plasma proteins that are abundant in vasogenic edema and increased by clot resorption are harmful to the brain. Patients with a higher ratio of edema to hematoma volume have been retrospectively shown to have poorer outcomes [ 32 ] . Thrombin, as well as hemoglobin and its breakdown products, has been demonstrated to be neurotoxic via glutamate-mediated excitotoxicity, exacerbate acute perihematoma edema, and contribute to disruption of the blood-brain barrier [ 33 ] . Additionally, interleukin-1 and matrix metalloproteinases (MMPs) are upregulated in the neurons and astrocytes of the perihematoma region. Perihematoma edema is reduced in experimental models of ICH with both MMP-9 knockout mice and with administration of IL-1 receptor antagonists [ 34, 35 ] . Overall, the potentially toxic effects of iron as well as a range of infl ammatory mediators have led to the concept of "neurohemoinfl ammation" as a descriptor for a variety of different pathways which may result in secondary brain injury after ICH. These small molecules and their biochemical signaling pathways, or even iron-chelating agents such as deferoxamine, represent promising targets for future acute ICH therapy which are being investigated in animal and translational research [36] [37] [38] . A phase 1 dose-fi nding safety study is underway to evaluate deferoxamine mesylate in patients with acute ICH and holds potential to be the fi rst therapeutic intervention to specifi cally target "neurohemoinfl ammation" [ 39, 40 ] .
Concern for perihematoma ischemia has been another area of active investigation regarding mechanisms of ICH-related secondary injury in ICH. Cerebral blood fl ow studies using SPECT and MRI perfusion and diffusion have attempted to demonstrate a perihematoma penumbra that is at risk for additional injury and neuronal loss due to hypoperfusion [41] [42] [43] . The signifi cance of these fi ndings has been called into question by more recent CT perfusion studies that failed to show a penumbra, by PET studies that have found that these areas of "penumbra" may in fact be appropriately perfused in the setting of reduced metabolic activity, and by animal studies which suggest a zone of hypoperfusion without impaired oxygen metabolism [44] [45] [46] . A recent PET study demonstrated transient focal increase of glucose metabolism in a subset of patients with ICH that was present at ~3 days postictus but not at 1 nor 7 days [ 47 ] ; this lends further credence to the hypothesis of an evolving metabolic (but not ischemic) penumbra surrounding an acute hematoma [ 48 ] .
In the past, ICH has been thought of as a monophasic event with an initial hemorrhage that grew to its maximal size within moments, with rehemorrhage or hematoma expansion as rare events suggestive of coagulopathy or underlying vascular anomaly. However, numerous studies have now demonstrated that hematoma expansion is common early after acute ICH, even in the absence of an underlying lesion or coagulopathy. In a single-center prospective study, substantial hematoma growth, defi ned as >33% enlargement of the baseline hematoma volume, occurred during the fi rst day in 38% of patients who underwent CT scanning within 3 h of the initial ictus; 26% of patients demonstrated this enlargement within 1 h after initial CT scan [ 49 ] . Retrospective studies have found similar rates of rebleeding ranging from 18% to 36% with substantially lower rates of delayed rebleeding beyond 6 h of 2-10% [50] [51] [52] . Of note, when examining the placebo group of a phase 2 study of recombinant factor VIIa (rFVIIa) for acute ICH, 73% of patients demonstrated some degree of hematoma expansion over the fi rst day [ 53 ] . Because hematoma expansion is an important independent determinant of overall outcome, it is now being strongly considered as a potential target for intervention with hemostatic agents or even aggressive blood pressure control in order to limit hematoma growth [ 54, 55 ] .
Clinical Presentation and Diagnosis
The clinical presentation of ICH is characterized by the sudden onset of focal neurologic dysfunction that is generally accompanied by severe headache. Prior to the advent of modern CT and MRI neuroimaging, the presence of headache with the ictus was often cited as the defi ning characteristic of hemorrhagic stroke. However, headache at onset does not reliably distinguish ICH since it occurs in up to 30% of patients with ischemic strokes [ 56 ] . Patients with large hemispheric ICH that acts as a mass or who have signifi cant IVH that obstructs cerebrospinal fl uid drainage may have profoundly elevated intracranial pressure (ICP) and often present with nausea and vomiting, in addition to focal neurologic deficits that may rapidly progress to herniation and coma. The distinct presentation of coma with pinpoint pupils should immediately alert the practitioner to the possibility of a pontine tegmental hemorrhage. Various baseline clinical and neuroimaging characteristics are predictive of outcome in ICH. These include hematoma volume, Glasgow Coma Scale (GCS) score, IVH, advanced age, infratentorial ICH location, and premorbid cognitive impairment [57] [58] [59] [60] [61] [62] [63] .
The widespread use of CT scanning has made the diagnosis of ICH relatively straightforward, and it remains the most widely used neuroimaging technique. Acute stroke MRI protocols utilizing susceptibility weighted imaging that exploit the paramagnetic properties of hemoglobin can also accurately identify ICH with very high sensitivity and specifi city as compared to CT ( Fig. 9.2 ) [ 64 ] . Intracranial vascular imaging with conventional angiography has a high yield in identifying vascular malformations in cases of ICH in younger patients (age <45), atypical hemorrhage location for hypertension, or if the patient has no history of hypertension [ 65 ] . We also advocate for vascular imaging in cases where the hemorrhage appears to be originating in the ventricle as the yield of angiography is quite high in this population [ 66 ] . Multislice CT angiography has been proposed as a surrogate for conventional angiography in the investigation of neurovascular disorders [ 67 ] , but the sensitivity is insufficiently adequate if a vascular malformation is not identifi ed to advocate foregoing conventional angiography [ 68, 69 ] . Additionally, in cases of acute ICH, CT angiography with early and delayed image acquisition may be helpful in identifying patients with active contrast extravasation as this is a predictor of hematoma expansion and worsened outcome [70] [71] [72] [73] [74] [75] [76] . This type of imaging could theoretically help target interventions toward patients most likely to experience ongoing hematoma expansion, but this has not yet been tested prospectively. 
Management of ICH Blood Pressure
Elevated blood pressure (BP) is extremely common in the setting of acute ICH. Blood pressure management in this setting remains controversial because of concerns over balancing the competing interests of limiting hematoma expansion or rebleeding while avoiding the theoretical risk of secondary ischemic brain injury by hypoperfusing perihematoma brain parenchyma. Studies have confl icted over whether elevated blood pressure predisposes to hematoma expansion after acute ICH [77] [78] [79] . However, recent studies have suggested that perihematoma ischemia is unlikely to be a major contributor to ICH-related brain injury in most cases [ 45, 46, 80 ] . Even so, there still remains a relative dearth of data to support specifi c blood pressure goal recommendations and recent American Heart Association/ American Stroke Association guidelines for the management of ICH continue to recommend individualized blood pressure goals based upon individual patient characteristics such as presumed etiology of hemorrhage (hypertension versus underlying vascular anomaly), history of chronic hypertension and baseline blood pressure, and known or suspected major vessel arterial stenosis where a signifi cant decline in blood pressure could cause secondary organ damage [ 81 ] . These guidelines suggest the following potential approaches: [ 1 ] if SBP is >200 mmHg or mean arterial pressure (MAP) >150 mmHg then consider aggressive BP reduction with a continuous intravenous infusion and frequent monitoring of BP and neurologic examination; [ 2 ] if SBP is >180 mmHg or MAP is >130 mmHg and there is evidence of or suspicion of elevated ICP, then consider monitoring ICP and reducing BP using intermittent or continuous intravenous medications to keep the cerebral perfusion pressure (CPP) between 60 and 80 mmHg; [ 3 ] if SBP is >180 or MAP is >130 and there is no evidence of or suspicion of elevated ICP, then consider a modest reduction of BP (e.g., MAP £ 110 mmHg or target BP £ 160/90 mmHg) using continuous or intermittent IV medications to control BP with frequent monitoring of BP and neurologic examination. While the choice of BP-lowering agent should be individualized based on factors such as heart rate and medical comorbidities (e.g., renal or heart failure), our usual preference is to use agents that preferentially affect cardiac output or are arterial vasodilators, such as bolus doses of intravenous labetalol or continuous intravenous infusion of nicardipine. We try to avoid medications which might cause signifi cant venodilation, such as hydralazine or nitroprusside. Several clinical trials are currently ongoing to test whether aggressive BP treatment limits hematoma expansion and improves clinical outcome after ICH [ 82, 83 ] . A recently published multicenter randomized prospective trial demonstrated that intensive lowering of SBP to goal <140 as opposed to SBP to goal <180 decreased the absolute risk of signifi cant hematoma growth (defi ned as ³ 33% of baseline hematoma volume) by 8% without increasing the rate of adverse events [ 84 ] ; a larger clinical trial based upon these results is underway to test whether this lower SBP goal can improve clinical outcomes [ 85 ] . Another recent dose escalation study that was presented at the 2009 International Stroke Conference which examined the tolerability and safety of targeting three different BP goals (SBP 170-200, SBP 140-170, SBP 110-140) using nicardipine infusion found that patients tolerated acute lowering of SBP to the three tiers without signifi cant differences in neurologic deterioration between the three tiers [ 86 ] .
Coagulopathy
ICH is more frequent in patients treated with anticoagulants and fi brinolytics, and the risk of warfarin-related ICH increases with increasing INR [ 87, 88 ] . Warfarin-related ICH is associated with an even higher rate of mortality than ICH in the absence of coagulopathy, and ongoing bleeding in warfarin-related ICH continues for a more prolonged duration [ 21, 89 ] . The obvious goal is to urgently reverse the coagulopathy as soon as possible. While this has historically been done using vitamin K and fresh frozen plasma (FFP), it is now recognized that this approach is suboptimal and often leads to excessively slow correction or failure to correct the coagulopathy entirely [ 90 ] . Current guidelines [ 91 ] recommend the use of vitamin K 5-10 mg usually administered intravenously by slow push and concurrent treatment with a more rapidly acting reversal agent as it usually takes hours after vitamin K administration for reversal of warfarin-induced coagulopathy [ 92 ] . Full warfarin correction usually necessitates the administration of large volumes of FFP and the logistics surrounding cross matching, thawing, and infusion rates make this generally a slower option for correction. Consequently, recent interest has turned to the use of concentrated factor preparations such as prothrombin complex concentrate (PCC) or hemostatic agents such as recombinant factor VIIa. PCC administration generally reverses an elevated INR more rapidly than FFP [93] [94] [95] [96] and consequently may be more advantageous in limiting hematoma growth due to ongoing warfarin-related coagulopathy. However, in a study comparing PCC and FFP, there was no difference in hematoma growth between FFP and PCC in patients whose INR was corrected within 2 h [ 97 ] . This strongly suggests that it is timing of coagulopathy reversal, not a specifi c agent that makes the difference. Various current guidelines for warfarin reversal in the setting of life-threatening hemorrhage now emphasize the use of a rapid reversal agent such as PCC or rFVIIa in addition to vitamin K [ 91, 98, 99 ] .
Hemostatic Agents
The recognition that hematoma expansion worsens outcome and is common even in the absence of coagulopathy has generated signifi cant interest in the potential use of hemostatic agents to limit hematoma growth. Developed as an agent for the treatment of a subset of hemophiliac patients, rFVIIa has now been investigated in a wide range of bleeding disorders in patients with normal coagulation, including ICH [ 100, 101 ] . In a phase 2 trial, 399 acute ICH patients who had initial CT diagnosis within 3 h of symptom onset received either placebo or one of three doses of rFVIIa (40, 80, or 160 m g/kg) within 1 h of CT scan. Overall, patients who received rFVIIa had less hematoma expansion and this translated to a lower risk of mortality and improved functional outcome, despite a small increase in thrombotic events such as myocardial infarction [ 55 ] . Given these encouraging results, a larger phase 3 trial including 821 patients was conducted with essentially the same inclusion criteria, but comparing placebo and two doses of rFVIIa (20 and 80(m)g/ kg). In this pivotal phase 3 trial, hematoma expansion was once again dramatically reduced by treatment with rFVIIa; however, there was no statistically signifi cant change in the proportion of patients who died or were severely disabled. The total number of thromboembolic events was similar in the three groups, but the number of arterial thromboembolic events was higher in the group treated with 80 m g/kg when compared with placebo. A major critique of the phase 2 trial results is that the placebo group did worse than historical controls, and a major critique of the phase 3 trial results is that there were a larger proportion of patients with IVH in the 20 and 80 m g/kg groups compared with placebo [ 102 ] . Post hoc analysis of the phase 3 trial identifi ed a subgroup of patients that might show a robust radiographic and clinical benefi t from treatment with rFVIIa ( £ 70 years of age, ICH volume <60 ml, IVH volume <5 ml, time from onset to treatment £ 2.5 h); this subgroup effect was also confi rmed in the phase 2 cohort [ 103 ] . Studies are being considered using these clinical or other neuroimaging selection criteria (e.g., CTA contrast extravasation). However, at present, hemostatic therapy cannot be recommended as routine treatment for ICH patients without coagulopathy.
Antiplatelet Agents and ICH
There are confl icting reports as to the role of prior antiplatelet therapy on hematoma expansion and outcome for patients presenting with ICH and the 2007 AHA/ASA ICH guidelines do not address this issue [ 81, [104] [105] [106] [107] [108] . Consequently, there is wide heterogeneity in clinical practice ranging from practitioners who advocate platelet transfusion in patients with ICH while taking antiplatelet agents, such as aspirin or clopidrogel, to those who advocate the use of laboratory tests for platelet function and to those who choose not to treat. Examination of the placebo group from a neuroprotective ICH study did not demonstrate an association between antiplatelet use and hematoma expansion or outcome [ 107 ] . In contrast, recently published work on antiplatelet use and platelet function has suggested that the results of platelet activity assays (but not merely the history of aspirin usage) correlated with occurrence of IVH, a greater ICH score, hematoma growth, and worse outcomes in ICH [109] [110] [111] . Given the widespread use of antiplatelet agents, further clarifi cation of the impact of antiplatelet use and platelet dysfunction on ICH occurrence, growth, and outcome is an important future direction.
Intensive Care Management: Intracranial Pressure
Patients with moderate or large ICH or IVH often have increased ICP or hydrocephalus that warrants consideration of treatment. The AHA/ASA guidelines advocate a graded stepwise approach with initial routine use of less invasive measures prior to instituting more invasive measures. These less invasive measures include elevation of the head of the bed to 30°, maintenance of the neck in a neutral position to facilitate jugular venous drainage, and adequate analgesia and sedation. More invasive measures include CSF drainage via an extraventicular drain (EVD) placed directly into the ventricles. An EVD allows continuous measurement of ICP as well as drainage of CSF to treat elevated ICP, but does carry a small risk of hemorrhage or infection. Osmotic agents such as mannitol and hypertonic saline may be used to decrease ICP, but overuse of mannitol may cause hypovolemia, renal failure, and cerebral vasoconstriction. Neuromuscular blockade may also be considered in patients with refractory elevated ICP but is likely associated with an increased risk of infection and critical illness neuromuscular disease. While hyperventilation may rapidly reduce elevated ICP by causing cerebral arterial vasoconstriction, this effect is generally transient (few hours) and reduces cerebral blood fl ow which might potentially engender secondary brain injury. Thus, we tend to reserve hyperventilation for use as a temporizing measure in preparation for other more defi nitive medical or surgical treatments. Finally, barbiturate coma may be considered in patients that have failed other therapies but is associated with a signifi cant risk of hypotension and requires continuous electroencephalographic monitoring to titrate effective dosing. Induced hypothermia from 32 to 34°C may also be attempted for a brief period. The use of barbiturate coma and induced hypothermia have not been systematically investigated in ICH and are considered as salvage second-tier therapies at present.
Intensive Care Management: Fever, Glucose, DVT Prophylaxis, Seizure Prophylaxis
Fever is a common occurrence in patients with ICH and increased fever duration is associated with poor outcomes [ 112 ] . Thus, fever should be aggressively treated even as appropriate testing for systemic infection is being undertaken. Hyperglycemia on admission is predictive of 14-day and 28-day mortality in patients with ICH [ 113, 114 ] . Intensive insulin therapy treatment of hyperglycemia during critical illness has been shown to decrease systemic morbidity and mortality as well as decrease the incidence of critical illness polyneuropathy and seizures [ 115, 116 ] . Thus, it is reasonable to vigilantly avoid hyperglycemia in patients with ICH and to institute aggressive approaches to achieve normoglycemia. Even so, randomized trials specifi cally in patients with ICH have not been performed and concerns have been raised about the possibility of hypoglycemic episodes and their particularly detrimental effects in patients with brain injury [ 117 ] .
Deep venous thrombosis (DVT) and pulmonary embolism are frequent in patients presenting with ICH, and DVT is diagnosed in approximately 2% of patients during their acute hospitalization [ 118 ] . In one study, the combination of compression stockings plus intermittent pneumatic compression decreased the rate of asymptomatic DVT detected at day 10 from 15.9% to 4.7% in patients with ICH [ 119 ] . The other intervention study published to date in patients specifi cally with ICH examined the initiation of low-dose subcutaneous heparin for DVT prophylaxis [ 120 ] . Unfractionated heparin 5,000 units three times a day was initiated on the second, fourth, or tenth day following presentation with ICH. There was a statistically signifi cant decrease in the incidence of pulmonary embolism in those patients in whom heparin was started on the second day when compared with the other groups, and importantly there was no increase in intracranial rebleeding. This small study suggests that low-dose subcutaneous heparin can be started as early as the second day in patients who present with ICH and that it may decrease the incidence of pulmonary embolism without profoundly increasing the risk of hematoma expansion or new ICH during hospitalization. In retrospective analysis of patients with ICH at another center, the initiation of the low molecular weight heparin (LMWH) enoxaparin at low dose (20 mg) after the onset of stroke was not associated with hematoma enlargement nor decrease in the number of venous thromboembolic complications [ 121 ] . Another study prospectively followed 97 patients with ICH in whom LMWH (enoxaparin or dalteparin at dosing appropriate for DVT prophylaxis) was initiated within 36 h after admission with ICH and found no increased risk of hematoma enlargement [ 122 ] . Whether subcutaneous unfractionated heparin or LMWH is superior in patients with ICH has not been specifi cally tested.
There is a risk of seizures (especially nonconvulsive) in the acute period after ICH, with one study of continuous EEG monitoring (cEEG) in critically ill ICH patients fi nding that 18 of 63 (28%) had electrographic seizures. In this study, seizures were independently associated with increased midline shift and a trend toward poor outcome [ 123 ] . Another prospective cohort study demonstrated that early prophylactic therapy with phenobarbital decreased the risk of developing seizures within the fi rst 30 days in patients with lobar ICH [ 124 ] . However, two recent studies have raised concerns over the utility and safety of prophylactic anticonvulsants, specifically phenytoin, in patients with ICH. In a prospective cohort study, phenytoin use was associated with worsened outcome [ 125 ] . In a retrospective analysis of the placebo arm of an ICH neuroprotective clinical trial, prophylactic anticonvulsants were associated with worse outcomes without decreasing the rate of early or late seizures [ 126 ] . Thus, we do not advocate the use of prophylactic anticonvulsants (especially phenytoin) in patients with ICH, but do use cEEG commonly in ICH patients with unexplained decreased level of consciousness.
Surgery
The decision to undertake surgical evacuation of the hematoma in spontaneous ICH remains controversial and fraught with clinical uncertainty, being still signifi cantly infl uenced by the bias of practitioners and consultants caring for the patient [ 127 ] . Until recently there had only been a few small mostly single-center trials, the preponderance of which did not favor a mandatory approach of craniotomy for evacuation of the hematoma in ICH. These prior trials set the stage for a landmark study entitled the International Surgical Trial in Intracranial Haemorrhage (STICH) [ 128 ] . This international, multicenter trial randomized 1,033 patients presenting within 72 h of ictus of spontaneous supratentorial ICH in which the local neurosurgeon decided that there was clinical equipoise about whether or not the patient would benefi t from surgery. The patient was randomized to either early surgical intervention (within 24 h of randomization) or initial medical management. The primary outcome measure was death or disability as measured by the extended Glasgow Outcome Score (GOS) at 6 months; different outcome cutpoints were used depending on expected prognosis from the initial hemorrhage [ 129 ] . Method of hematoma evacuation and medical management were left to the discretion of local treating physicians and outcomes were assessed using questionnaires sent to the patients or their families; 506 patients were randomized to early surgical intervention; 530 were randomized to initial medical management, but 26% of these patients ultimately underwent surgery for hematoma evacuation (mostly due to neurologic deterioration) [ 130 ] . In an intentionto-treat analysis, early surgery was neither benefi cial nor harmful as there was no statistically signifi cant difference in either mortality or functional outcome. Given the design limitations, the results of STICH cannot be used to conclude that surgical evacuation has no role in supratentorial ICH. However, it does demonstrate that a largescale surgical ICH trial can be successfully completed and that early surgery is unlikely to be a panacea for most patients. Of note, prespecifi ed subgroup analyses identifi ed that patients with hematomas <1 cm from the cortical surface and patients who underwent craniotomy as the surgical procedure had a nonsignifi cant trend toward benefi t with early surgery. Based upon the results of the subgroup analysis, a second international multicenter trial (STICH II) is currently underway to test early hematoma evacuation versus initial conservative management in patients with lobar hematoma 1 cm or less from the cortical surface [ 131 ] .
There are a number of case series which report that patients with spontaneous cerebellar hemorrhage who present with large cerebellar hematomas (>3 cm in diameter) or with compression of the brain stem or hydrocephalus may still have a favorable outcome with surgical intervention [ 132, 133 ] . However, there has not been a prospective randomized trial of surgery for cerebellar ICH analogous to STICH. Even so, cerebellar ICH is generally considered as a potentially surgical lesion by most neurologists and neurosurgeons, especially in patients with obstructive hydrocephalus or clinical deterioration. The 2007 AHA/ASA ICH management guidelines recommend surgical removal of the hematoma as soon as possible in patients with cerebellar hemorrhage >3 cm who are deteriorating neurologically or who have brain stem compression and/or hydrocephalus from ventricular obstruction [ 81 ] .
A number of minimally invasive surgical alternatives to open craniotomy have also been considered and studied in small case series or pilot clinical trials. These techniques include: simple aspiration of the hematoma [ 134 ] , mechanical aspiration with a screw and suction technique [ 135 ] , instillation of a thrombolytic such as urokinase or recombinant tissue plasminogen activator into the hematoma with aspiration of contents [ 136, 137 ] , and endoscopic aspiration of the hematoma with lavage of the hematoma cavity and photocoagulation of oozing vessels [ 138 ] . NIH-sponsored multicenter trials are currently underway comparing catheter-directed t-PA treatment for hematoma evacuation versus conventional medical management for patients presenting with ICH [ 139 ] as well as for IVH [ 140 ] .
Prognostication and the Conundrum of the Self-Fulfi lling Prophecy
Recent work has suggested that the use of do-not resuscitate (DNR) orders or other measures of care limitations (such as withdrawal of medical support) early after ICH may independently infl uence patient outcome even when accounting for other factors [ 24, 25, [141] [142] [143] . Furthermore, studies have found substantial variation in the use of these care limitations across hospitals and physicians [ 22, 24, 143 ] . This has raised the concern that perceived poor prognosis very early after ICH might lead to care limitations and death or disability in patients who might otherwise recover if aggressive treatment was instituted. In a single-center retrospective cohort study, Becker and colleagues found that the single most important factor predicting outcome in patients with ICH was the level of care provided; withdrawal of life support negated the predictive value of all other candidate variables to predict outcome [ 22 ] . They also found a wide range of prognostication for individual patients amongst physicians of different levels of training and specialty. In another study using discharge records from a large cohort of over 8,000 ICH patients treated at over 200 hospitals in California, the rate at which a hospital used DNR orders within 24 h of hospital admission was an independent risk factor for death in the individual ICH patient [ 24 ] . This suggests that the overall milieu of care in a hospital (aggressive versus nihilistic) may have an important impact on outcome, even in the absence of a proven treatment. Current AHA/ASA ICH guidelines recommend initial aggressive full care and avoidance of new DNR orders within the fi rst 24 h after ICH [ 81 ] .
Conclusion
Although ICH remains without an approved treatment proven to clearly decrease morbidity and mortality, the last decade has seen notable advances in the understanding of ICH pathophysiology and potential treatments. Recognition of the importance of hematoma expansion and other causes of secondary injury has helped clarify injury mechanisms and suggest new treatments. Major large trials of both medical and surgical therapy for acute ICH have demonstrated the feasibility of clinical trials for ICH treatment, which has lagged behind studies for the interventional treatment of ischemic stroke and SAH. Ongoing basic research has also suggested new targets for treatment that are beginning to be studied in the clinical setting. Given these major advances, optimism about future advances in ICH care is justifi ed.
